Biotech | August 16, 2022
PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Company appoints five new independent directors to reconstituted board
Company appoints five new independent directors to reconstituted board
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Man lost 54 Kgs in 6 months with MGB procedure
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Subscribe To Our Newsletter & Stay Updated
